• Users Online: 692
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2020  |  Volume : 22  |  Issue : 1  |  Page : 70

Proadrenomedullin and prognostic value for pneumonia


1 Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India

Date of Submission30-Aug-2019
Date of Decision10-Oct-2019
Date of Acceptance08-Nov-2019
Date of Web Publication30-Apr-2020

Correspondence Address:
Dr. Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ejop.ejop_72_19

Rights and Permissions

How to cite this article:
Joob B, Wiwanitkit V. Proadrenomedullin and prognostic value for pneumonia. Eurasian J Pulmonol 2020;22:70

How to cite this URL:
Joob B, Wiwanitkit V. Proadrenomedullin and prognostic value for pneumonia. Eurasian J Pulmonol [serial online] 2020 [cited 2020 Oct 19];22:70. Available from: https://www.eurasianjpulmonol.com/text.asp?2020/22/1/70/283633



Dear Editor,

We read the publication on “Proadrenomedullin (proADM) determining clinical severity and analyzing prognostic value for pneumonia” with a great interest.[1] Demirsoy et al. concluded that “Using proADM levels alone to predict pneumonia prognosis and mortality and deciding upon a therapy setting make no sense, although in consideration of previous studies, proADM would be useful as a supplementary contributor to clinical severity scores.[1]” Indeed, the diagnostic value of proADM in pneumonia is interesting. Several reports, including to the present report, show that proADM might be useful. Nevertheless, there are many important considerations. First, proADM might be altered due to other medical underlying factors. The heart disease is another important medical problem that can result in alteration on proADM level.[2] Furthermore, other underlying lung disease such as chronic obstructive lung disease can also result in alteration of proADM level.[3]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Demirsoy S, Okutan O, Kartaloglu Z, Tas D, Ayten O, Canoglu K. Proadrenomedullin determining clinical severity and analyzing prognostic value for pneumonia. Eurasian J Pulmonol 2019;21:97-106.  Back to cited text no. 1
  [Full text]  
2.
Nishikimi T, Nakagawa Y. Adrenomedullin as a biomarker of heart failure. Heart Fail Clin 2018;14:49-55.  Back to cited text no. 2
    
3.
Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): A qualitative clinical review. Clin Chem Lab Med 2015;53:521-39.  Back to cited text no. 3
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed299    
    Printed24    
    Emailed0    
    PDF Downloaded45    
    Comments [Add]    

Recommend this journal